Donor's APOL1 Risk Genotype and "Second Hits" Associated With De Novo Collapsing Glomerulopathy in Deceased Donor Kidney Transplant Recipients: A Report of 5 Cases

被引:40
|
作者
Chang, Jae-Hyung [1 ]
Husain, S. Ali [1 ]
Santoriello, Dominick [2 ]
Stokes, Michael B. [2 ]
Miles, Clifford D. [3 ]
Foster, Kirk W. [4 ]
Li, Yifu [1 ]
Dale, Leigh-Anne [1 ]
Crew, Russell J. [1 ]
Cohen, David J. [1 ]
Kiryluk, Krzysztof [1 ]
Gharavi, Ali G. [1 ]
Mohan, Sumit [1 ,5 ,6 ]
机构
[1] Columbia Univ Coll Phys & Surg, Dept Med, Div Nephrol, New York, NY USA
[2] Columbia Univ Coll Phys & Surg, Dept Pathol & Cell Biol, 630 W 168th St, New York, NY 10032 USA
[3] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA
[4] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA
[5] Columbia Univ, Mailman Sch Publ Hlth, Columbia Univ Renal Epidemiol CURE Grp, New York, NY USA
[6] Columbia Univ, Dept Epidemiol, New York, NY USA
关键词
FOCAL SEGMENTAL GLOMERULOSCLEROSIS; VARIANTS; GENE; PROGRESSION;
D O I
10.1053/j.ajkd.2018.05.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The presence of 2 APOL1 risk variants (G1/G1, G1/G2, or G2/G2) is an important predictor of focal segmental glomerulosclerosis (FSGS) and chronic kidney disease in individuals of African descent. Although recipient APOL1 genotype is not associated with allograft survival, kidneys from deceased African American donors with 2 APOL1 risk variants demonstrate shorter graft survival. We present a series of cases of presumed de novo collapsing FSGS in 5 transplanted kidneys from 3 deceased donors later identified as carrying 2 APOL1 risk alleles, including 2 recipients from the same donor whose kidneys were transplanted in 2 different institutions. Four of these recipients had viremia in the period preceding the diagnosis of collapsing FSGS. Cytomegalovirus and BK virus infection were present in 3 and 1 of our 5 cases, respectively, around the time that collapsing FSGS occurred. We discuss viral infections, including active cytomegalovirus infection, as possible "second hits" that may lead to glomerular injury and allograft failure in these recipients. Further studies to identify additional second hits are necessary to better understand the pathologic mechanisms of donor APOL1-associated kidney disease in the recipient.
引用
收藏
页码:134 / 139
页数:6
相关论文
共 50 条
  • [31] Development of De Novo Donor Specific Antibodies (dnDSAs) Not the Presence of Pre-Transplant Donor Specific Antibodies (Pre-DSAs) Increase Rejection Risk in Crossmatch Negative Kidney Transplant Recipients
    Khamash, H.
    Archambault, L.
    Buras, M.
    Kosiorek, H.
    Pando, M.
    Reddy, K.
    Kaplan, B.
    Heilman, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 417 - 417
  • [32] De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
    Cioni, Michela
    Nocera, Arcangelo
    Innocente, Annalisa
    Tagliamacco, Augusto
    Trivelli, Antonella
    Basso, Sabrina
    Quartuccio, Giuseppe
    Fontana, Iris
    Magnasco, Alberto
    Drago, Francesca
    Gurrado, Antonella
    Guido, Ilaria
    Compagno, Francesca
    Garibotto, Giacomo
    Klersy, Catherine
    Verrina, Enrico
    Ghiggeri, Gian Marco
    Cardillo, Massimo
    Comoli, Patrizia
    Ginevri, Fabrizio
    JOURNAL OF IMMUNOLOGY RESEARCH, 2017, 2017
  • [33] Kidney transplant from HCV viremic donors to HCV-negative recipients and risk for de novo donor specific antibodies and acute rejection
    Daloul, Reem
    Sureshkumar, Kalathil
    Schnelle, Kendra
    Von Stein, Lauren
    Logan, April
    Pesavento, Todd
    CLINICAL TRANSPLANTATION, 2023, 37 (02)
  • [34] HLA-DQ heterodimer mismatch number is associated with de novo donor-specific antibody development in pediatric kidney transplant recipients
    Sigurjonsdottir, V. K.
    Wang, L.
    Piburn, K.
    Turudi, D.
    Grimm, P.
    Zhang, M. M.
    HUMAN IMMUNOLOGY, 2024, 85 : 95 - 96
  • [35] Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience
    Jarmi, Tambi
    Abdelmoneim, Yousif
    Li, Zhuo
    Jebrini, Abdullah
    Elrefaei, Mohamed
    TRANSPLANT IMMUNOLOGY, 2023, 77
  • [36] Association of PIRCHE-II score with anti-donor T-cell response and risk of de novo donor-specific antibody production in kidney transplant recipients
    Yamane, Hiroaki
    Ide, Kentaro
    Tanaka, Yuka
    Ohira, Masahiro
    Tahara, Hiroyuki
    Shimizu, Seiichi
    Sakai, Hiroshi
    Nakano, Ryosuke
    Ohdan, Hideki
    TRANSPLANT IMMUNOLOGY, 2024, 87
  • [37] Differential Clinical Outcomes in Kidney Transplant Recipients With De Novo C1q+and C1q-Donor Specific Antibodies
    Ajaimy, M.
    Colovai, A.
    Calp, S.
    Lindower, J.
    Melamed, M.
    Akalin, E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [38] Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial
    Dantal, Jacques
    Berthoux, Francois
    Moal, Marie-Christine
    Rostaing, Lionel
    Legendre, Christophe
    Genin, Robert
    Toupance, Olivier
    Moulin, Bruno
    Merville, Pierre
    Rerolle, Jean-Philippe
    Bayle, Francois
    Westeel, Pierre Francois
    Glotz, Denis
    Kossari, Niloufar
    Lefrancois, Nicole
    Charpentier, Bernard
    Quere, Stephane
    Di Giambattista, Fabienne
    Cassuto, Elisabeth
    TRANSPLANT INTERNATIONAL, 2010, 23 (11) : 1084 - 1093
  • [39] HEPATITIS A AND B VACCINATION ASSOCIATED WITH DE NOVO DSA TO A PREVIOUS DONOR'S HLA AND A POSITIVE FCXM TO A POTENTIAL SECOND DONOR: SUCCESSFUL KIDNEY TRANSPLANTATION AFTER DESENSITIZATION.
    Norin, Allen J.
    Sumrani, Nabil
    Hochman, David
    Das, Ballabh
    Salifu, Moro
    John, Devon
    HUMAN IMMUNOLOGY, 2015, 76 : 152 - 152
  • [40] Clinical Outcome of Kidney Transplant Recipients with C1q-Binding De Novo Donor Specific Antibodies: A Single-Center Experience
    Marinaki, Smaragdi
    Vittoraki, Angeliki
    Tsiakas, Stathis
    Kofotolios, Ioannis
    Darema, Maria
    Ioannou, Sofia
    Vallianou, Kalliopi
    Boletis, John
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)